Loading stock data…
MNOV
$1.40+0.01 (+0.72%)
Market ClosedLast close May 1
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MediciNova, Inc. in the Healthcare sector is trading at $1.40. The stock is currently 29% below its 52-week high of $1.96, remaining 0.0% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why MNOV maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.40
Potential Upside
5%
Whystock Fair Value$1.47
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$69.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.85%
Volume
Today's trading volume
15,577
Recent News
Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls
Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls
MediciNova: Q4 Earnings Snapshot
LA JOLLA, Calif. AP) — MediciNova Inc. MNOV) on Friday reported a loss of $2.8 million in its fourth quarter.
ATA Creativity Global Among 3 Promising Penny Stocks
As the U.S. stock market faces a challenging period with major indexes posting weekly losses and Treasury yields reaching a four-month high, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking growth prospects outside of the mainstream market giants. Despite being considered somewhat niche today, penny stocks can still offer significant potential when backed by...
MediciNova: Q3 Earnings Snapshot
LA JOLLA, Calif. AP) — MediciNova Inc. MNOV) on Wednesday reported a loss of $3.1 million in its third quarter.
3 Penny Stocks With Market Caps Over $80M To Consider
As the United States stock market continues to post gains, boosted by strong performances from tech giants like Amazon, investors are exploring diverse opportunities across various sectors. Penny stocks, while often considered a relic of past trading days, still hold relevance as they offer potential growth at lower price points. When backed by solid financials and robust fundamentals, these smaller or newer companies can defy expectations and present significant returns.